Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes

Satish K Garg, Stuart A Weinzimer, William V Tamborlane, Bruce A Buckingham, Bruce W Bode, Timothy S Bailey, Ronald L Brazg, Jacob Ilany, Robert H Slover, Stacey M Anderson, Richard M Bergenstal, Benyamin Grosman, Anirban Roy, Toni L Cordero, John Shin, Scott W Lee, Francine R Kaufman, Satish K Garg, Stuart A Weinzimer, William V Tamborlane, Bruce A Buckingham, Bruce W Bode, Timothy S Bailey, Ronald L Brazg, Jacob Ilany, Robert H Slover, Stacey M Anderson, Richard M Bergenstal, Benyamin Grosman, Anirban Roy, Toni L Cordero, John Shin, Scott W Lee, Francine R Kaufman

Abstract

Background: The safety and effectiveness of the in-home use of a hybrid closed-loop (HCL) system that automatically increases, decreases, and suspends insulin delivery in response to continuous glucose monitoring were investigated.

Methods: Adolescents (n = 30, ages 14-21 years) and adults (n = 94, ages 22-75 years) with type 1 diabetes participated in a multicenter (nine sites in the United States, one site in Israel) pivotal trial. The Medtronic MiniMed® 670G system was used during a 2-week run-in phase without HCL control, or Auto Mode, enabled (Manual Mode) and, thereafter, with Auto Mode enabled during a 3-month study phase. A supervised hotel stay (6 days/5 nights) that included a 24-h frequent blood sample testing with a reference measurement (i-STAT) occurred during the study phase.

Results: Adolescents (mean ± standard deviation [SD] 16.5 ± 2.29 years of age and 7.7 ± 4.15 years of diabetes) used the system for a median 75.8% (interquartile range [IQR] 68.0%-88.4%) of the time (2977 patient-days). Adults (mean ± SD 44.6 ± 12.79 years of age and 26.4 ± 12.43 years of diabetes) used the system for a median 88.0% (IQR 77.6%-92.7%) of the time (9412 patient-days). From baseline run-in to the end of study phase, adolescent and adult HbA1c levels decreased from 7.7% ± 0.8% to 7.1% ± 0.6% (P < 0.001) and from 7.3% ± 0.9% to 6.8% ± 0.6% (P < 0.001, Wilcoxon signed-rank test), respectively. The proportion of overall in-target (71-180 mg/dL) sensor glucose (SG) values increased from 60.4% ± 10.9% to 67.2% ± 8.2% (P < 0.001) in adolescents and from 68.8% ± 11.9% to 73.8% ± 8.4% (P < 0.001) in adults. During the hotel stay, the proportion of in-target i-STAT® blood glucose values was 67.4% ± 27.7% compared to SG values of 72.0% ± 11.6% for adolescents and 74.2% ± 17.5% compared to 76.9% ± 8.3% for adults. There were no severe hypoglycemic or diabetic ketoacidosis events in either cohort.

Conclusions: HCL therapy was safe during in-home use by adolescents and adults and the study phase demonstrated increased time in target, and reductions in HbA1c, hyperglycemia and hypoglycemia, compared to baseline.

Trial registration: Clinicaltrials.gov identifier: NCT02463097.

Keywords: Continuous glucose monitoring; Hybrid closed loop; Hyperglycemia; Hypoglycemia; Insulin pump; Sensor; Type 1 diabetes.

Conflict of interest statement

The following authors: Drs. Garg, Weinzimer, Buckingham, Bode, Bailey, Brazg, Ilany, Slover, Anderson, and Bergenstal served as principal investigators for this study and received compensation and research support from Medtronic. Dr. Tamborlane served as a consultant in the study and received compensation from Medtronic. Drs. Grosman, Roy, Cordero, Shin, Lee, and Kaufman, employees of Medtronic, participated in data analysis and/or critical review of the manuscript.

Figures

FIG. 1.
FIG. 1.
Sensor glucose profiles during the run-in and study phase. Median and interquartile range of sensor glucose values throughout the day and night, beginning at midnight (00, on x-axis), in (A) adolescents and (B) adults. The gray band and dotted line represent data from the run-in phase; the pink band and solid line represent data from the study phase.

References

    1. Miller KM, Foster NC, Beck RW, et al. : Current state of type 1 diabetes treatment in the U.S.: Updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971–978
    1. Weinzimer SA, Steil GM, Swan KL, et al. : Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008;31:934–939
    1. Trevitt S, Simpson S, Wood A: Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development? J Diabetes Sci Technol 2016;10:714–723
    1. Kovatchev BP, Breton M, Man CD, et al. : In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol 2009;3:44–55
    1. Atlas E, Nimri R, Miller S, et al. : MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care 2010;33:1072–1076
    1. Breton M, Farret A, Bruttomesso D, et al. : Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes 2012;61:2230–2237
    1. Buckingham BA, Beck RW, Ruedy KJ, et al. : Diabetes Research in Children Network Study Group; Type 1 Diabetes TrialNet Study Group. The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis. Diabetes Technol Ther 2013;15:401–408
    1. Castle JR, Engle JM, El Youssef J, et al. : Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010;33:1282–1287
    1. O'Grady MJ, Retterath AJ, Keenan DB, et al. : The use of an automated, portable glucose control system for overnight glucose control in adolescents and young adults with type 1 diabetes. Diabetes Care 2012;35:2182–2187
    1. Russell SJ, El-Khatib FH, Nathan DM, et al. : Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care 2012;35:2148–2155
    1. Kovatchev BP, Renard E, Cobelli C, et al. : Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificial pancreas. Diabetes Care 2013;36:1851–1858
    1. Nimri R, Muller I, Atlas E, et al. : Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis. Pediatr Diabetes 2014;15:91–99
    1. Phillip M, Battelino T, Atlas E, et al. : Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013;368:824–833
    1. Kovatchev B, Cheng P, Anderson SM, et al. : Feasibility of long-term closed-loop control: a multicenter 6-month trial of 24/7 automated insulin delivery. Diabetes Technol Ther 2016. [DOI: 10.1089/dia.2016.0333]
    1. Nimri R, Muller I, Atlas E, et al. : MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care 2014;37:3025–3032
    1. Tauschmann M, Allen JM, Wilinska ME, et al. : Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 2016;39:1168–1174
    1. Thabit H, Elleri D, Leelarathna L, et al. : Unsupervised home use of an overnight closed-loop system over 3–4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. Diabetes Obes Metab 2015;17:452–458
    1. Thabit H, Tauschmann M, Allen JM, et al. : Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 2015;373:2129–2140
    1. Steil GM, Palerm CC, Kurtz N, et al. : The effect of insulin feedback on closed loop glucose control. J Clin Endocrinol Metab 2011;96:1402–1408
    1. Roy A, Grosman B, Parikh N, et al. : Physiological and technical stress test for Medtronic's artificial pancreas system in a supervised outpatient setting. Diabetes Technol Ther 2015;17:A17
    1. Ly TT, Roy A, Grosman B, et al. : Day and night closed-loop control using the integrated Medtronic hybrid closed-loop system in type 1 diabetes at diabetes camp. Diabetes Care 2015;38:1205–1211
    1. Ly TT, Weinzimer SA, Maahs DM, et al. : Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. Pediatr Diabetes 2016;10.1111/pedi.12399
    1. Grosman B, Ilany J, Roy A, et al. : Hybrid closed-loop insulin delivery in type 1 diabetes during supervised outpatient conditions. J Diabetes Sci Technol 2016;10:708–713
    1. de Bock MI, Roy A, Cooper MN, et al. : Feasibility of outpatient 24-hour closed-loop insulin delivery. Diabetes Care 2015;38:e186–e187
    1. Bergenstal RM, Garg S, Weinzimer SA, et al. : Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 2016;316:1407–1408
    1. Ruiz JL, Sherr JL, Cengiz E, et al. : Effect of insulin feedback on closed-loop glucose control: a crossover study. J Diabetes Sci Technol 2012;6:1123–1130
    1. Dasari PS, Gandomani BS, Teague AM, et al. : Glycemic variability is associated with markers of vascular stress in adolescents. J Pediatr 2016;172:47–55
    1. Jung HS: Clinical implications of glucose variability: chronic complications of diabetes. Endocrinol Metab 2015;30:167–174
    1. de Bock M, Dart J, Roy A, et al. : Exploration of the performance of a hybrid closed loop insulin delivery algorithm that includes insulin delivery limits designed to protect against hypoglycemia. J Diabetes Sci Technol 2016. [DOI: 10.1177/1932296816668876]
    1. Brazg R, Christiansen M, Bode B, et al. : Accuracy of a fourth-generation glucose sensor throughout its functional life. Diabetes 2016;65:A226
    1. Bailey TS, Ahmann A, Brazg R, et al. : Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor. Diabetes Technol Ther 2014;16:277–283
    1. Keenan DB, Mastrototaro JJ, Zisser H, et al. : Accuracy of the enlite 6-day glucose sensor with Guardian and Veo calibration algorithms. Diabetes Technol Ther 2012;14:225–231
    1. Bergenstal RM, Klonoff DC, Garg SK, et al. : Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369:224–232
    1. Choudhary P, Olsen BS, Conget I, et al. : Hypoglycemia prevention and user acceptance of an insulin pump system with predictive low glucose management. Diabetes Technol Ther 2016;18:288–291
    1. Kovatchev BP, Renard E, Cobelli C, et al. : Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care 2014;37:1789–1796
    1. Russell SJ, El-Khatib FH, Sinha M, et al. : Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014;371:313–325
    1. van Bon AC, Luijf YM, Koebrugge R, et al. : Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. Diabetes Technol Ther 2014;16:131–136
    1. Tauschmann M, Allen JM, Wilinska ME, et al. : Home use of day-and-night hybrid closed-loop insulin delivery in suboptimally controlled adolescents with type 1 diabetes: a 3-week, free-living, randomized crossover trial. Diabetes Care 2016;39:2019–2025
    1. Food and Drug Administration, Center for Devices and Radiological Health: MiniMed 670G System approval letter, September 28, 2016. (accessed January11, 2017)

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren